688202 Stock Overview
A drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Shanghai Medicilon Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥34.95 |
52 Week High | CN¥84.09 |
52 Week Low | CN¥23.30 |
Beta | 0.77 |
11 Month Change | 44.18% |
3 Month Change | 22.93% |
1 Year Change | -49.41% |
33 Year Change | -90.73% |
5 Year Change | n/a |
Change since IPO | -3.52% |
Recent News & Updates
Shanghai Medicilon Inc. (SHSE:688202) Might Not Be As Mispriced As It Looks
Sep 27Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?
Jun 07Shareholder Returns
688202 | CN Life Sciences | CN Market | |
---|---|---|---|
7D | 1.1% | -0.5% | 2.7% |
1Y | -49.4% | -29.1% | 4.6% |
Return vs Industry: 688202 underperformed the CN Life Sciences industry which returned -29.1% over the past year.
Return vs Market: 688202 underperformed the CN Market which returned 4.6% over the past year.
Price Volatility
688202 volatility | |
---|---|
688202 Average Weekly Movement | 12.0% |
Life Sciences Industry Average Movement | 9.9% |
Market Average Movement | 7.6% |
10% most volatile stocks in CN Market | 11.5% |
10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 688202's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688202's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 2,415 | Chunlin Chen | www.medicilon.com.cn |
Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems.
Shanghai Medicilon Inc. Fundamentals Summary
688202 fundamental statistics | |
---|---|
Market cap | CN¥4.67b |
Earnings (TTM) | -CN¥269.57m |
Revenue (TTM) | CN¥1.01b |
4.6x
P/S Ratio-17.3x
P/E RatioIs 688202 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688202 income statement (TTM) | |
---|---|
Revenue | CN¥1.01b |
Cost of Revenue | CN¥1.01b |
Gross Profit | CN¥1.83m |
Other Expenses | CN¥271.40m |
Earnings | -CN¥269.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
Earnings per share (EPS) | -2.02 |
Gross Margin | 0.18% |
Net Profit Margin | -26.57% |
Debt/Equity Ratio | 9.0% |
How did 688202 perform over the long term?
See historical performance and comparison